Bayer AG (XSWX:BAYN) Revenue: CHF41,973 Mil (TTM As of Mar. 2026)


XSWX:BAYN Bayer AG XSWX:BAYN
48 GF Score
Price CHF42.49
GF Value CHF24.74
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bayer AG Revenue?

Bayer AG XSWX:BAYN 48 Revenue is CHF41,973 Mil as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 48/100 and a GF Value™ of CHF24.74 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Bayer AG's revenue for the three months ended in Mar. 2026 was CHF12,201 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was CHF41,973 Mil. Bayer AG's Revenue per Share for the three months ended in Mar. 2026 was CHF12.42. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF42.72.

Warning Sign:

Bayer AG revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Bayer AG was -2.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -3.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 1.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Bayer AG's highest 3-Year average Revenue per Share Growth Rate was 11.10% per year. The lowest was -11.20% per year. And the median was 2.10% per year.


Bayer AG  (XSWX:BAYN) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Bayer AG Revenue Related Terms


Bayer AG Revenue Historical Data

* Premium members only.

The historical data trend for Bayer AG's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Revenue Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45,874.13 50,072.51 44,925.28 43,511.95 42,527.77

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,123.13 10,072.61 9,026.20 10,673.23 12,200.88

XSWX:BAYN vs LLY, JNJ, ABBV: Revenue Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Revenue distribution charts can be found below:

* The bar in red indicates where Bayer AG's Revenue falls into.


XSWX:BAYN
48GF Score
Bayer AG XSWX:BAYN
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF41,973 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of CHF41,973 Mil mean?
Bayer AG (XSWX:BAYN) has a Revenue of CHF41,973 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Bayer AG and its competitors.
Is Bayer AG's Revenue too high?
Bayer AG's current Revenue is CHF41,973 Mil. Overall, Bayer AG has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Revenue compare to LLY and JNJ?
Bayer AG's Revenue of CHF41,973 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Bayer AG and its competitors. Bayer AG's current Revenue is CHF41,973 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.74, compared to a current price of CHF42.49 — trading 71.7% above its estimated fair value. The current Revenue is CHF41,973 Mil. Bayer AG's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Revenue is CHF41,973 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF42.49 is trading 71.7% above its estimated GF Value™ of CHF24.74. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Revenue: CHF41,973 Mil
  • GF Value™: CHF24.74 vs. price of CHF42.49 (71.7% above fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
48GF Score

Get the complete analysis for XSWX:BAYN

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF42.49
Price
CHF24.74
GF Value